Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical features of ISCMs, per-patient basis (n = 49 patients)
Feature Prevalence
Sex 
    Female 26 (53%)
Primary malignancy 
    Lung carcinoma 24 (49%)
    Breast carcinoma 7 (14%)
    Melanoma 5 (10%)
    CNS origin 4 (8%)
    Renal cell carcinoma 3 (6%)
    Other 6 (12%)
Timing of primary tumor diagnosis 
    ISCM presentation preceded primary tumor diagnosis 10 (20%)
    ISCM diagnosis preceded primary tumor diagnosis 5 (10%)
Dominant presenting symptoms 
    Weakness 28 (57%)
    Sensory symptoms 8 (16%)
    Bowel and/or bladder dysfunction 5 (10%)
    Pain 4 (8%)
    Asymptomatic 4 (8%)
Time interval, median (range) 
    Duration of symptoms at clinical presentation (n = 44) 2 weeks (0.1–32)
    Primary tumor diagnosis to ISCM presentation (n = 38) 1.8 years (0–19.3)
    Primary tumor diagnosis to ISCM diagnosis (n = 44) 1.6 years (0–19.5)

Feature	Prevalence
Sex
Female	26 (53%)
Primary malignancy
Lung carcinoma	24 (49%)
Breast carcinoma	7 (14%)
Melanoma	5 (10%)
CNS origin	4 (8%)
Renal cell carcinoma	3 (6%)
Other	6 (12%)
Timing of primary tumor diagnosis
ISCM presentation preceded primary tumor diagnosis	10 (20%)
ISCM diagnosis preceded primary tumor diagnosis	5 (10%)
Dominant presenting symptoms
Weakness	28 (57%)
Sensory symptoms	8 (16%)
Bowel and/or bladder dysfunction	5 (10%)
Pain	4 (8%)
Asymptomatic	4 (8%)
Time interval, median (range)
Duration of symptoms at clinical presentation (n = 44)	2 weeks (0.1–32)
Primary tumor diagnosis to ISCM presentation (n = 38)	1.8 years (0–19.3)
Primary tumor diagnosis to ISCM diagnosis (n = 44)	1.6 years (0–19.5)